✦ LIBER ✦

REPEAT reaffirms the benefits of retreatment with PEG IFN-α-2a

✍ Scribed by Crofskey, S

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

583 Safety of peginterferon α-2a (40KD)

✍ D. Jensen; F. Andreone; Y. Benhamou; Y. Horsmans; M. Diago; A. Olveira Martins; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 234 KB

78 The HCV NS3 protease inhibitor SCH 50

✍ S. Zeuzem; C. Sarrazin; F. Wagner; R. Rouzier; N. Forestier; S. Gupta; M. Hussai 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 102 KB

O.091 Early prediction of response to Pe

✍ P. Ciccorossi; P. Colombatto; A. Maina; L. Civitano; F. Oliveri; R. Sacco; B. Co 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 270 KB

P.273 Early results of peg-IFN α-2a trea

✍ M.H. Strain; M. Patrascu; R.D. Strain 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Pharmacokinetics and response of obese p

✍ Brian Bressler; Ka Wang; Joseph F. Grippo; E. Jenny Heathcote 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 639 KB

A health economic model to assess the co

✍ S. Gerkens; M. Nechelput; L. Annemans; B. Peraux; M. Mouchart; C. Beguin; Y. Hor 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB